Printer Friendly

CONMED CORPORATION ANNOUNCES FDA MARKET APPROVAL OF LOOP ELECTRODES FOR GYNECOLOGY

 CONMED CORPORATION ANNOUNCES FDA MARKET APPROVAL OF
 LOOP ELECTRODES FOR GYNECOLOGY
 UTICA, N.Y., Feb. 20 /PRNewswire/ -- CONMED Corporation (NASDAQ: CNMD) today reported that it has received FDA approval to market its specialized disposable Loop Electrodes for Gynecology. These Loop Electrodes will be used in a hospital, clinic or in-office procedure for diagnosing and treating cervical lesions.
 Known as LLETZ (Large Loop Excision of the Transformation Zone), the procedure uses eletrosurgery and Loop Electrodes to remove suspected ceri?cal tissue to diagnose the extent of possible disease while simultaneously removing any diseased tissue. LLETZ has the advantage of being performed in a physician's office under local anesthesia allowing the patient to return to normal activity quickly. The company estimates that a majority of the 32,000 practicing obstetricians-gynecologists in the United States will be incorporating this technique in their practice.
 CONMED Corporation and its subsidiary Aspen Labs also manufacture and sell electrosurgical generators and the hand-held electrosurgical "pencils" used to deliver the electrosurgical energy to the Loop Electrode, as well as the electrosurgical ground pads needed to perform the procedure. With the FDA approval to market its Loop Electrodes, the company offers a complete system for performing the LLETZ procedures.
 CONMED is s leading supplier of electrosurgery products to the healthcare industry. The company distributes its products worldwide from manufacturing and warehousing facilities in Utica, N.Y. and Denver.
 -0- 2/20/92
 /CONTACT: Robert D. Shallish of CONMED Corporation, 315-797-8375, ext. 2219/
 (CNMD) CO: CONMED Corporation ST: New York IN: MTC SU: PDT


LC -- CL006 -- 4074 02/20/92 11:12 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 20, 1992
Words:263
Previous Article:THE COCA-COLA COMPANY INCREASES QUARTERLY DIVIDEND 17 PERCENT; BOARD OF DIRECTORS RECOMMENDS 2-FOR-1 SPLIT TO SHARE OWNERS
Next Article:DU PONT NAMES MOBLEY V-P, COMMUNICATIONS
Topics:


Related Articles
CONMED ANNOUNCES SECOND QUARTER 1992 EARNINGS
CONMED ANNOUNCES EARNINGS ESTIMATE
CONMED ANNOUNCES NEW PRODUCT
CONMED CORPORATION ANNOUNCES F.D.A. MARKETING PERMISSION FOR MODULAR INSTRUMENT SYSTEM
EVEREST MEDICAL SIGNS PRODUCT SUPPLY AGREEMENT WITH CONMED
CONMED EARNINGS PER SHARE IMPROVES 145 PERCENT
CONMED FILES REGISTRATION STATEMENT
Angeion Begins FDA Approved Clinicals of Sentinel 2010 ICD System
PROSURG, Inc. Has Been Awarded the Patent for Multiple Needle Ablation Device For Treatment of Urological and Gynecological Disorders
PROSURG, Inc. Has Received FDA Clearance for BPH Indication for TURP and Prostate Surgery Using Electrosurgical Probes and Devices

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters